Meyer Burger Technology has successfully completed a capital increase raising gross proceeds of approximately CHF 207 million. The transaction con
Walder Wyss has advised the buyer of the Park Hyatt Zurich. It is a joint partnership among Trinity Investments, funds managed by Oaktree Capital Management, and funds managed by UBS Asset Management. The joint partnership
The Swiss special purpose issuance vehicle Xtrackers Digital Markets ETC AG, simultaneously launched two series of crypto-linked Exchange Traded Products (ETPs). This falls under its program for the issuance of cryptocurrency-focused ETPs for professional and
Altenburger has advised Helarb Management SA, with respect to the acquisition of Emailtec SA. The Altenburger team was led by partner Manuel Moor. Emailtec is one of the leaders in the renovation of bathtubs and
Liberty Media Corporation has announced its acquisition of Dorna Sports from Bridgepoint and Canada Pension Plan Investment Board, S.L. Liberty are the exclusive commercial rights holder to the MotoGP World Championship.. The transaction is
Ina Invest Holding, has completed a merger by absorption of its subsidiary, Ina Invest. This has resulted in an increase in its market capitalisation by around 40%. Implenia, the former co-owner of Ina Invest, was compensated
On April 3, 2024, Meyer Burger Technology AG (SIX: MBTN) announced the successful completion of its rights offering, raising gross proceeds of CHF 206.75m. Shares not subscribed by shareholders were placed with institutional investors at the prevailing
Singapore-based Venturi Partners have invested USD 25 million in the Philippines-focused grocery store chain Dali. Venturi Partners joins Philippines-based private equity firm Navegar, Malaysia-headquartered buyout company Creador, and multilateral lender the Asian Development Bank (ADB). Lenz &
Niederer Kraft Frey has advised Clariant AG, on the placement of a CHF 200 million bond, with a term to maturity of three years (Tranche A), as well as a CHF 150 million bond with a term
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development,
